FGF19 and hepatocellular carcinoma: Another Phase 2 clinical trial (NCT07010497) is currently recruiting to test the safety and efficacy of Irapragratinib in Combination with Atezolizumab and Bevacizumab for HCC with FGF19 overexpression.